Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | HBB | P68871 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribose (Furanose) SCHEMBL10787751 | 1.00 | LMNA (0.49) | LMNAMTORALDH1A1DNMT1TP53 | |
| Ribose (Furanose) SCHEMBL8833 | 0.78 | LMNA (0.49) | LMNAMTORALDH1A1DNMT1TP53 | |
| Ribose (Furanose) SCHEMBL3341287 | 0.78 | LMNA (0.49) | LMNAMTORALDH1A1DNMT1TP53 | |
| Ribose (Furanose) SCHEMBL2325834 | 0.78 | LMNA (0.49) | LMNAMTORALDH1A1DNMT1TP53 | |
| Ribose (Furanose) SCHEMBL142622 | 0.78 | LMNA (0.49) | LMNAMTORALDH1A1DNMT1TP53 | |
| 2-Aminopurine SCHEMBL5529464 | 0.77 | LMNA (0.41) | LMNAMTORALDH1A1DNMT1TP53 | |
| 2-Aminopurine SCHEMBL28775710 | 0.77 | ALDH1A1 (0.59) | LMNAMTORALDH1A1DNMT1TP53 | |
| Ribose (Furanose) SCHEMBL16620262 | 0.77 | PNP (0.44) | LMNAMTORALDH1A1DNMT1TP53 | |
| Isoguanine SCHEMBL11527542 | 0.77 | PNP (0.39) | LMNAMTORALDH1A1DNMT1TP53 | |
| Ribose (Furanose) SCHEMBL628713 | 0.77 | LMNA (0.48) | LMNAMTORALDH1A1DNMT1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170231911-A1 | METHODS AND COMPOSITIONS FOR IMPROVING OUTCOMES OF LIPOSOMAL CHEMOTHERAPY | MERRIMACK PHARMACEUTICALS, INC. | 2017-08-17 | — | — | US | claimed |
| WO-2014169067-A1 | COMPOSITIONS FOR IMPROVING OUTCOMES OF LIPOSOMAL CHEMOTHERAPY | MERRIMACK PHARMACEUTICALS, INC. (US) | 2014-10-16 | — | — | WO | claimed |
| US-8580857-B2 | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy | AU JESSIE L-S (US) | 2013-11-12 | — | — | US | claimed |
| US-20110142794-A1 | Methods and Compositions to Determine the Chemosensitizing Dose of Suramin Used in Combination Therapy | AU JESSIE L-S | 2011-06-16 | — | — | US | claimed |
| US-7309696-B2 | Compositions and methods for targeting cancer cells | WAKE FOREST UNIVERSITY (US) | 2007-12-18 | — | — | US | claimed |
| EP-1429713-A4 | METHODS AND COMPOSITIONS TO DETERMINE THE CHEMOSENSITIZING DOSE OF SURAMIN USED IN COMBINATION THERAPY | AU JESSIE L S (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2007011760-A2 | INHIBITORS OF MITOTIC KINESIN | KALYPSYS, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| WO-2007011759-A2 | INHIBITORS OF MITOTIC KINESIN | KALYPSYS, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| WO-2007011721-A1 | INHIBITORS OF MITOTIC KINESIN | KALYPSYS, INC. (US) | 2007-01-25 | — | — | WO | claimed |
| US-20040180955-A1 | Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy | AU JESSIE L-S (US) | 2004-09-16 | — | — | US | claimed |
| EP-1429713-A2 | METHODS AND COMPOSITIONS TO DETERMINE THE CHEMOSENSITIZING DOSE OF SURAMIN USED IN COMBINATION THERAPY | Au, Jessie L.S. (US) | 2004-06-23 | — | — | EP | claimed |
| EP-0909184-B1 | TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES | UPJOHN CO (US) | 2003-09-17 | — | — | EP | claimed |
| WO-2003026574-A2 | METHODS AND COMPOSITIONS TO DETERMINE THE CHEMOSENSITIZING DOSE OF SURAMIN USED IN COMBINATION THERAPY | AU JESSIE L-S (US) | 2003-04-03 | — | — | WO | claimed |
| US-4684630-A | WATER UNSTABLE AZACYTIDINE AND 5-AZACYTOSINE ARABINOSE IN AN AQUEOUS DILUTED DMSO AND DIMETHYLACETAMIDE SOLUTION | REPTA ARNOLD J | 1987-08-04 | — | — | US | claimed |
| CN-117441022-A | Sequential electroporation method | 美克斯细胞有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20230390422-A1 | OLIGONUCLEOTIDE-BASED THERAPEUTICS AND USES THEREOF | SPEER TOD (US) | 2023-12-07 | — | — | US | disclosed |
| EP-4218730-B1 | LIPOSOMES USEFUL FOR DRUG DELIVERY | IPSEN BIOPHARM LTD (GB) | 2023-11-01 | — | — | EP | disclosed |
| US-5216011-A | Solvent mixture consisting of propylene glycol and water | BRISTOL-MYERS SQUIBB CO. (US) | 1993-06-01 | — | — | US | disclosed |
| EP-0415430-A1 | Stable solutions of mitomycin C | Bristol-Myers Squibb Company (US) | 1991-03-06 | — | — | EP | disclosed |
| US-4684630-A | WATER UNSTABLE AZACYTIDINE AND 5-AZACYTOSINE ARABINOSE IN AN AQUEOUS DILUTED DMSO AND DIMETHYLACETAMIDE SOLUTION | REPTA ARNOLD J | 1987-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230390422-A1 | OLIGONUCLEOTIDE-BASED THERAPEUTICS AND USES THEREOF | POLRMT, DCLRE1B, POLM | LMNA 337/4885MTOR 4672/4885ALDH1A1 3320/4885 |
| US-20170231911-A1 | METHODS AND COMPOSITIONS FOR IMPROVING OUTCOMES OF LIPOSOMAL CHEMOTHERAPY | LIPA, SGMS1, SGMS2 | LMNA 2531/4885MTOR 3742/4885ALDH1A1 3841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.